PatientsVille.com Logo


Tarceva Medical Research Studies

Up-to-date List of Tarceva Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Tarceva Medical Research Studies

Rank Status Study
1 Recruiting A Study of First-line Maintenance Tarceva (Erlotinib) Versus Tarceva at Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer After Chemotherapy
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva];   Drug: Placebo
Outcome Measures: Overall survival (OS): First-line maintenance Tarceva versus Tarceva at time of disease progression;   Progression-free survival (PFS): First-line maintenance Tarceva versus placebo (tumour assessments according to RECIST criteria);   Overall response rate (ORR): First-line maintenance Tarceva versus placebo;   Disease control rate (DCR): First-line maintenance Tarceva versus placebo;   Safety: Incidence of adverse events
2 Recruiting Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Condition: Non Small Cell Lung Cancer
Intervention: Drug: BKM120 and Erlotinib
Outcome Measures: Progression Free Survival (PFS);   Evaluate toxicity of the BKM120/erlotinib combination using CTCAE v4.0.;   Assess anti-tumor activity;   Correlate specific tumor biomarkers with treatment efficacy (exploratory)
3 Not yet recruiting A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
Conditions: Non-small Cell Lung Cancer;   Advanced Solid Malignancies
Interventions: Drug: Theophylline;   Drug: Erlotinib
Outcome Measures: The lowest effective dose of theophylline that will prevent or maximally ameliorate erlotinib's diarrhea at the standard dose of erlotinib at 150 mg/day taken daily for 28 days every 28 days;   The highest dose of erlotinib that can be administered with theophylline and can be administered with an acceptable safety profile
4 Not yet recruiting Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: gemcitabine; cisplatin or carboplatin; erlotinib;   Drug: erlotinib
Outcome Measures: Progression-free survival;   Overall Survival
5 Recruiting A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Erlotinib;   Dietary Supplement: Silybin-phytosome
Outcome Measures: Tumour response rate;   Safety assessment
6 Unknown  2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib plus docetaxel or pemetrexed;   Drug: erlotinib
Outcome Measures: Imaging;   Safety
7 Recruiting Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
Condition: EGFR-Mutant Lung Cancer
Intervention: Drug: erlotinib
Outcome Measures: to determine the maximum tolerated dose (MTD);   to evaluate the safety profile;   Progression Free Survival (PFS);   Response rate (RR);   Overall survival (OS)
8 Unknown  Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Erlotinib (Tarceva®)
Outcome Measures: To determinate the viability and toxicity profile of Erlotinib + 3D Radiotherapy treatment (% of patients presenting toxicity 3-4 during the treatment).;   The progression-free survival.;   1-year survival.;   Overall survival.;   Objective response rate, according to RECIST criteria.
9 Recruiting Erlotinib in Combination With Pralatrexate in Advanced Malignancies
Conditions: Advanced Cancers;   Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Pralatrexate
Outcome Measures: Maximum Tolerated Dose (MTD) of Erlotinib with Pralatrexate;   Tumor Response
10 Recruiting Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Erlotinib
Outcome Measures: Safety of twice a day oral 150 mg Erlotinib dosing;   Composite overall response rate (CORR);   6-month progression free survival (PFS);   Overall survival (OS)
11 Not yet recruiting Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: pemetrexed disodium;   Drug: carboplatin;   Drug: cisplatin;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
Outcome Measures: Progression free survival using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1;   Overall survival;   Objective response rate defined as partial response (PR) and complete response (CR) using RECIST version 1.1;   Number of patients with each worst grade toxicity grades 3-5 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4
12 Recruiting Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations
Condition: Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib;   Biological: bevacizumab;   Other: laboratory biomarker analysis
Outcome Measures: Progression free survival (PFS) of erlotinib and bevacizumab versus that of erlotinib alone in untreated advanced non-small cell lung cancer patients who have activating EGFR mutations;   Overall survival of erlotinib and bevacizumab versus erlotinib alone;   Response rate (complete or partial) to each treatment;   Progression free survival of patients with different mutation types (exon deletion 19 vs. exon 21 L858R);   Types and the frequency of treatment-related adverse events for erlotinib and bevacizumab and erlotinib alone;   Correlation of EGFR mutations detected in plasma DNA with those detected in tumor DNA;   Prevalence of EGFR T790M resistance mutations from pretreatment tumor biopsies using more sensitive mutation detection methods;   Effect of EGFR T790M on progression free survival;   Predictive value of plasma VEGF-A levels on progression free survival in patients treated with erlotinib alone or in combination with bevacizumab
13 Recruiting Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: Erlotinib
Outcome Measures: Rate of dose limiting toxicities of each subject;   Overall survival;   progression-free survival;   Best tumor response;   Changes in the level of serum tumor marker cancer antigen (CA) 19-9;   Adverse events related to pulse dose erlotinib and gemcitabine
14 Recruiting Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: docetaxel;   Drug: pemetrexed;   Drug: Erlotinib
Outcome Measure: Progression-free survival (PFS)
15 Recruiting Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Conditions: Brain Cancer;   Glioblastoma Multiforme
Interventions: Drug: Vorinostat;   Drug: Erlotinib;   Drug: Temozolomide
Outcome Measures: Maximum Tolerated Dose (MTD);   Progression Free Survival (PFS)
16 Recruiting Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Metastatic;   Non-small Cell Lung Cancer Recurrent
Intervention: Drug: MLN8237 and Erlotinib
Outcome Measures: Safety and tolerability of the combination treatment (Phase I);   MTD of alisertib when given in combination with standard dose erlotinib hydrochloride (Phase I);   PFS (Phase II);   PK parameters of erlotinib hydrochloride and alisertib, including, but not limited to Cmax, Tmax, and AUC 0-tlast;   ORR (Phase II);   DOR (Phase II);   TTP (Phase II);   OS (Phase II);   AEs, SAEs, and assessments of clinical laboratory values (Phase II)
17 Unknown  Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Docetaxel and Erlotinib;   Drug: Erlotinib
Outcome Measures: Percentage of patients without disease progression after 6 months of treatment.;   Progression-free survival;   Duration of Response;   Overall Response Rate;   Disease Control Rate;   Overall survival;   Safety profile
18 Recruiting A Study of Second-Line Therapy With Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib [Tarceva];   Drug: gemcitabine;   Drug: cisplatin
Outcome Measures: Progression free survival (PFS), defined as time from randomization until either disease progression on second-line treatment or death from any cause after disease progression on first-line treatment.;   Incidence of adverse events
19 Recruiting FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
Condition: Lung Cancer
Interventions: Drug: DOTAP:Chol-fus1;   Drug: Erlotinib;   Drug: Dexamethasone;   Drug: Diphenhydramine
Outcome Measures: Maximum Tolerated Dose (MTD) Level for Drug Treatment Combination;   Response Rate
20 Recruiting Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Condition: Lung Cancer
Interventions: Drug: Ruxolitinib;   Drug: Erlotinib
Outcome Measures: maximally tolerated dose (MTD) (Phase I);   Assess overall response rate (Phase I);   toxicity profile (Phase I);   survival (Phase II)

These studies may lead to new treatments and are adding insight into Tarceva etiology and treatment.

A major focus of Tarceva research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Tarceva